|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang
B, Li BS and Yang SM: The emergence of long non-coding RNAs in the
tumorigenesis of hepatocellular carcinoma. Cancer Lett.
360:119–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273 e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu CJ and Kao JH: Global perspective on
the natural history of chronic hepatitis B: role of hepatitis B
virus genotypes A to J. Semin Liver Dis. 33:97–102. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fukaya T and Tomari Y: MicroRNAs mediate
gene silencing via multiple different pathways in drosophila.
Molecular cell. 48:825–836. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takasaki S: Roles of microRNAs in cancers
and development. Methods Mol Biol. 1218:375–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang LF, Jiang S and Liu MF: MicroRNA
regulation and analytical methods in cancer cell metabolism. Cell
Mol Life Sci. 74:2929–2941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Castro D, Moreira M, Gouveia AM, Pozza DH
and De Mello RA: MicroRNAs in lung cancer. Oncotarget.
8:81679–81685. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferracin M, Lupini L, Mangolini A and
Negrini M: Circulating non-coding RNA as biomarkers in colorectal
cancer. Adv Exp Med Biol. 937:171–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Endzeliņš E, Melne V, Kalnina Z,
Lietuvietis V, Riekstiņa U, Llorente A and Linē A: Diagnostic,
prognostic and predictive value of cell-free miRNAs in prostate
cancer: A systematic review. Mol Cancer. 15:412016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bandiera S, Pfeffer S, Baumert TF and
Zeisel MB: miR-122-a key factor and therapeutic target in liver
disease. J Hepatol. 62:448–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wen J and Friedman JR: miR-122 regulates
hepatic lipid metabolism and tumor suppression. J Clin Invest.
122:2773–2776. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu
Y, Guo B, Shen Y, Landi D, et al: An insertion/deletion
polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′
untranslated region confers risk for hepatocellular carcinoma.
Carcinogenesis. 30:2064–2069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma J, Li T, Han X and Yuan H: Knockdown of
LncRNA ANRIL suppresses cell proliferation, metastasis, and
invasion via regulating miR-122-5p expression in hepatocellular
carcinoma. J Cancer Res Clin Oncol. 144:205–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Caviglia GP, Abate ML, Gaia S, Petrini E,
Bosco C, Olivero A, Rosso C, Ciancio A, Pellicano R, Saracco GM, et
al: Risk of hepatocellular carcinoma in HBV cirrhotic patients
assessed by the combination of miR-122, AFP and PIVKA-II.
Panminerva Med. 59:283–289. 2017.PubMed/NCBI
|
|
17
|
Ding Y, Yan JL, Fang AN, Zhou WF and Huang
L: Circulating miRNAs as novel diagnostic biomarkers in
hepatocellular carcinoma detection: A meta-analysis based on 24
articles. Oncotarget. 8:66402–66413. 2017.PubMed/NCBI
|
|
18
|
Naderi M, Pazouki A, Arefian E, Hashemi
SM, Jamshidi-Adegani F, Gholamalamdari O, Soudi S, Azadmanesh K,
Mirab Samiee S, Merat S, et al: Two triacylglycerol pathway genes,
CTDNEP1 and LPIN1, are down-regulated by hsa-miR-122-5p in
hepatocytes. Arch Iran Med. 20:165–171. 2017.PubMed/NCBI
|
|
19
|
Schisterman EF, Perkins NJ, Liu A and
Bondell H: Optimal cut-point and its corresponding Youden Index to
discriminate individuals using pooled blood samples. Epidemiology.
16:73–81. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Dai M, Zhu H, Li J, Huang Z, Liu
X, Huang Y, Chen J and Dai S: Evaluation on the diagnostic and
prognostic values of long non-coding RNA BLACAT1 in common types of
human cancer. Mol Cancer. 16:1602017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goldvaser H, Gutkin A, Beery E, Edel Y,
Nordenberg J, Wolach O, Rabizadeh E, Uziel O and Lahav M:
Characterisation of blood-derived exosomal hTERT mRNA secretion in
cancer patients: A potential pan-cancer marker. Br J Cancer.
117:353–357. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:(Database Issue). D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:(Database Issue). D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
26
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiao DD, Yang J, Lei XF, Mi GL, Li SL, Li
K, Xu CQ and Yang HL: Expression of microRNA-122 and microRNA-22 in
HBV-related liver cancer and the correlation with clinical
features. Eur Rev Med Pharmacol Sci. 21:742–747. 2017.PubMed/NCBI
|
|
28
|
Wang Y, Zhu P, Qiu J, Wang J, Zhu H, Zhu
Y, Zhang L, Zhu J, Liu X and Dong C: Identification and
characterization of interferon signaling-related microRNAs in
occult hepatitis B virus infection. Clin Epigenetics. 9:1012017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dai R, Peng F, Xiao X, Gong X, Jiang Y,
Zhang M, Tian Y, Xu Y, Ma J, Li M, et al: Hepatitis B virus X
protein-induced upregulation of CAT-1 stimulates proliferation and
inhibits apoptosis in hepatocellular carcinoma cells. Oncotarget.
8:60962–60974. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ali HEA, Abdel Hameed R, Effat H, Ahmed
EK, Atef AA, Sharawi SK, Ali M, Abd Elmageed ZY and Abdel Wahab AH:
Circulating microRNAs panel as a diagnostic tool for discrimination
of HCV-associated hepatocellular carcinoma. Clin Res Hepatol
Gastroenterol. 41:e51–e62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murray DD, Suzuki K, Law M, Trebicka J,
Neuhaus Nordwall J, Johnson M, Vjecha MJ, Kelleher AD and Emery S:
Circulating miR-122 and miR-200a as biomarkers for fatal liver
disease in ART-treated, HIV-1-infected individuals. Sci Rep.
7:109342017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su R, Cao S, Ma J, Liu Y, Liu X, Zheng J,
Chen J, Liu L, Cai H, Li Z, et al: Knockdown of SOX2OT inhibits the
malignant biological behaviors of glioblastoma stem cells via
up-regulating the expression of miR-194-5p and miR-122. Mol Cancer.
16:1712017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fan Y, Ma X, Li H, Gao Y, Huang Q, Zhang
Y, Bao X, Du Q, Luo G, Liu K, et al: miR-122 promotes metastasis of
clear-cell renal cell carcinoma by downregulating Dicer. Int J
Cancer. 142:547–560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rao M, Zhu Y, Zhou Y, Cong X and Feng L:
MicroRNA-122 inhibits proliferation and invasion in gastric cancer
by targeting CREB1. Am J Cancer Res. 7:323–333. 2017.PubMed/NCBI
|
|
35
|
Calatayud D, Dehlendorff C, Boisen MK,
Hasselby JP, Schultz NA, Werner J, Immervoll H, Molven A, Hansen CP
and Johansen JS: Tissue MicroRNA profiles as diagnostic and
prognostic biomarkers in patients with resectable pancreatic ductal
adenocarcinoma and periampullary cancers. Biomark Res. 5:82017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li XD, Yang YJ, Wang LY, Qiao SB, Lu XF,
Wu YJ, Xu B, Li HF and Gu DF: Elevated plasma miRNA-122, −140-3p,
−720, −2861, and −3149 during early period of acute coronary
syndrome are derived from peripheral blood mononuclear cells. PLoS
One. 12:e01842562017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Z, Li H, Chen S, Li Y, Cui Z and Ma
J: Knockdown of MicroRNA-122 protects H9c2 cardiomyocytes from
hypoxia-induced apoptosis and promotes autophagy. Med Sci Monit.
23:4284–4290. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Šatrauskienė A, Navickas R, Laucevičius A
and Huber HJ: Identifying differential miR and gene consensus
patterns in peripheral blood of patients with cardiovascular
diseases from literature data. BMC Cardiovasc Disord. 17:1732017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Blum A, Yehuda H, Geron N and Meerson A:
Elevated levels of miR-122 in serum may contribute to improved
endothelial function and lower oncologic risk following bariatric
surgery. Isr Med Assoc J. 19:620–624. 2017.PubMed/NCBI
|
|
40
|
Jones A, Danielson KM, Benton MC, Ziegler
O, Shah R, Stubbs RS, Das S and Macartney-Coxson D: miRNA
signatures of insulin resistance in obesity. Obesity (Silver
Spring). 25:1734–1744. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao H, Shen J, Daniel-MacDougall C, Wu X
and Chow WH: Plasma MicroRNA signature predicting weight gain among
Mexican-American women. Obesity (Silver Spring). 25:958–964. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Willeit P, Skroblin P, Moschen AR, Yin X,
Kaudewitz D, Zampetaki A, Barwari T, Whitehead M, Ramírez CM,
Goedeke L, et al: Circulating MicroRNA-122 is associated with the
risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes.
66:347–357. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bijkerk R, Florijn BW, Khairoun M, Duijs
JMGJ, Ocak G, de Vries APJ, Schaapherder AF, Mallat MJK, de Fijter
JW, Rabelink TJ, et al: Acute rejection after kidney
transplantation associates with circulating MicroRNAs and vascular
injury. Transplant Direct. 3:e1742017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang T, Li F, Geng W, Ruan Q and Shi W:
MicroRNA-122 ameliorates corneal allograft rejection through the
downregulation of its target CPEB1. Cell Death Discov. 3:170212017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Selmaj I, Cichalewska M, Namiecinska M,
Galazka G, Horzelski W, Selmaj KW and Mycko MP: Global exosome
transcriptome profiling reveals biomarkers for multiple sclerosis.
Ann Neurol. 81:703–717. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Trzybulska D, Bobjer J, Giwercman A and
Tsatsanis C: Serum microRNAs in male subfertility-biomarkers and a
potential pathogenetic link to metabolic syndrome. J Assist Reprod
Genet. 34:1277–1282. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Coulouarn C, Factor VM, Andersen JB,
Durkin ME and Thorgeirsson SS: Loss of miR-122 expression in liver
cancer correlates with suppression of the hepatic phenotype and
gain of metastatic properties. Oncogene. 28:3526–3536. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jin Y, Wang J, Han J, Luo D and Sun Z:
MiR-122 inhibits epithelial-mesenchymal transition in
hepatocellular carcinoma by targeting Snail1 and Snail2 and
suppressing WNT/β-cadherin signaling pathway. Exp Cell Res.
360:210–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miquelestorena-Standley E, Tallet A,
Collin C, Piver E, De Muret A, Salamé E, Bourlier P, Kervarrec T,
Guyétant S and Pagès JC: Interest of variations in microRNA-152 and
−122 in a series of hepatocellular carcinomas related to hepatitis
C virus infection. Hepatol Res. 48:566–573. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH,
Wang JH, Huang CM, Lee CM, Lin CY, Yen YH and Chiu YC: Circulating
microRNAs as biomarkers for diagnosis of early hepatocellular
carcinoma associated with hepatitis B virus. Int J Cancer.
138:714–720. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
El-Garem H, Ammer A, Shehab H, Shaker O,
Anwer M, El-Akel W and Omar H: Circulating microRNA, miR-122 and
miR-221 signature in Egyptian patients with chronic hepatitis C
related hepatocellular carcinoma. World J Hepatol. 6:818–824. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu Q, Zhang M, Tu J, Pang L, Cai W and Liu
X: MicroRNA-122 affects cell aggressiveness and apoptosis by
targeting PKM2 in human hepatocellular carcinoma. Oncol Rep.
34:2054–2064. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kanaan Z, Rai SN, Eichenberger MR, Barnes
C, Dworkin AM, Weller C, Cohen E, Roberts H, Keskey B, Petras RE,
et al: Differential microRNA expression tracks neoplastic
progression in inflammatory bowel disease-associated colorectal
cancer. Hum Mutat. 33:551–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tang Y, Zhao S, Wang J, Li D, Ren Q and
Tang Y: Plasma miR-122 as a potential diagnostic and prognostic
indicator in human glioma. Neurol Sci. 38:1087–1092. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang
Q, Chen L, Pang X, Leng W and Bi F: Plasma miR-122 and miR-192 as
potential novel biomarkers for the early detection of distant
metastasis of gastric cancer. Oncol Rep. 31:1863–1870. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yang J, Yuan Y, Yang X, Hong Z and Yang L:
Decreased expression of microRNA-122 is associated with an
unfavorable prognosis in childhood acute myeloid leukemia and
function analysis indicates a therapeutic potential. Pathol Res
Pract. 213:1166–1172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cho HJ, Kim JK, Nam JS, Wang HJ, Lee JH,
Kim BW, Kim SS, Noh CK, Shin SJ, Lee KM, et al: High circulating
microRNA-122 expression is a poor prognostic marker in patients
with hepatitis B virus-related hepatocellular carcinoma who undergo
radiofrequency ablation. Clin Biochem. 48:1073–1078. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H,
Xu N and Xie Y: Association of serum microRNA expression in
hepatocellular carcinomas treated with transarterial
chemoembolization and patient survival. PLoS One. 9:e1093472014.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xu Y, Bu X, Dai C and Shang C: High serum
microRNA-122 level is independently associated with higher overall
survival rate in hepatocellular carcinoma patients. Tumour Biol.
36:4773–4776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Köberle V, Kronenberger B, Pleli T, Trojan
J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem
S, Piiper A and Waidmann O: Serum microRNA-1 and microRNA-122 are
prognostic markers in patients with hepatocellular carcinoma. Eur J
Cancer. 49:3442–3449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cirera S, Birck M, Busk PK and Fredholm M:
Expression profiles of miRNA-122 and its target CAT1 in minipigs
(Sus scrofa) fed a high-cholesterol diet. Comp Med. 60:136–141.
2010.PubMed/NCBI
|
|
62
|
Munagala R, Aqil F, Vadhanam MV and Gupta
RC: MicroRNA ‘signature’ during estrogen-mediated mammary
carcinogenesis and its reversal by ellagic acid intervention.
Cancer Lett. 339:175–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
El-Abd NE, Fawzy NA, El-Sheikh SM and
Soliman ME: Circulating miRNA-122, miRNA-199a, and miRNA-16 as
biomarkers for early detection of hepatocellular carcinoma in
egyptian patients with chronic hepatitis C virus infection. Mol
Diagn Ther. 19:213–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang G, Zhao Y and Zheng Y:
MiR-122/Wnt/β-catenin regulatory circuitry sustains glioma
progression. Tumour Biol. 35:8565–8572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Khare D, Goldschmidt N, Bardugo A,
Gur-Wahnon D, Ben-Dov IZ and Avni B: Plasma microRNA profiling:
Exploring better biomarkers for lymphoma surveillance. PLoS One.
12:e01877222017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Conceição AL, Da Silva CT, Badial RM,
Valsechi MC, Stuqui B, Gonçalves JD, Jasiulionis MG, De Freitas
Calmon M and Rahal P: Downregulation of OCLN and GAS1 in clear cell
renal cell carcinoma. Oncol Rep. 37:1487–1496. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nientiedt M, Deng M, Schmidt D, Perner S,
Müller SC and Ellinger J: Identification of aberrant tRNA-halves
expression patterns in clear cell renal cell carcinoma. Sci Rep.
6:371582016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Jingushi K, Kashiwagi Y, Ueda Y, Kitae K,
Hase H, Nakata W, Fujita K, Uemura M, Nonomura N and Tsujikawa K:
High miR-122 expression promotes malignant phenotypes in ccRCC by
targeting occludin. Int J Oncol. 51:289–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Munari E, Marchionni L, Chitre A, Hayashi
M, Martignoni G, Brunelli M, Gobbo S, Argani P, Allaf M, Hoque MO
and Netto GJ: Clear cell papillary renal cell carcinoma: micro-RNA
expression profiling and comparison with clear cell renal cell
carcinoma and papillary renal cell carcinoma. Hum Pathol.
45:1130–1138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wang Z, Qin C, Zhang J, Han Z, Tao J, Cao
Q, Zhou W, Xu Z, Zhao C, Tan R and Gu M: MiR-122 promotes renal
cancer cell proliferation by targeting Sprouty2. Tumour Biol.
39:10104283176911842017.PubMed/NCBI
|
|
71
|
Wotschofsky Z, Busch J, Jung M,
Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller
K, Kristiansen G, et al: Diagnostic and prognostic potential of
differentially expressed miRNAs between metastatic and
non-metastatic renal cell carcinoma at the time of nephrectomy.
Clin Chim Acta. 416:5–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Papaconstantinou IG, Manta A, Gazouli M,
Lyberopoulou A, Lykoudis PM, Polymeneas G and Voros D: Expression
of microRNAs in patients with pancreatic cancer and its prognostic
significance. Pancreas. 42:67–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Schultz NA, Dehlendorff C, Jensen BV,
Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE,
Yilmaz M, Holländer NH, et al: MicroRNA biomarkers in whole blood
for detection of pancreatic cancer. JAMA. 311:392–404. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Carter JV, Roberts HL, Pan J, Rice JD,
Burton JF, Galbraith NJ, Eichenberger MR, Jorden J, Deveaux P,
Farmer R, et al: A highly predictive model for diagnosis of
colorectal neoplasms using plasma MicroRNA: Improving specificity
and sensitivity. Ann Surg. 264:575–584. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liu N, Jiang F, He TL, Zhang JK, Zhao J,
Wang C, Jiang GX, Cao LP, Kang PC, Zhong XY, et al: The roles of
MicroRNA-122 overexpression in inhibiting proliferation and
invasion and stimulating apoptosis of human cholangiocarcinoma
cells. Sci Rep. 5:165662015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lu W, Zhang Y, Zhou L, Wang X, Mu J, Jiang
L, Hu Y, Dong P and Liu Y: miR-122 inhibits cancer cell malignancy
by targeting PKM2 in gallbladder carcinoma. Tumour Biol. Nov
6–2015.(Epub ahead of print).
|
|
77
|
Walter BA, Valera VA, Pinto PA and Merino
MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer.
4:350–357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Venkatesan N, Deepa PR, Khetan V and
Krishnakumar S: Computational and in vitro investigation of
miRNA-Gene regulations in retinoblastoma pathogenesis: miRNA mimics
strategy. Bioinform Biol Insights. 9:89–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Xiao F, Chen J, Lian C, Han P and Zhang C:
Tumor necrosis factor-related apoptosis-inducing ligand induces
cytotoxicity specific to osteosarcoma by microRNA response
elements. Mol Med Rep. 11:739–745. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ergün S, Ulasli M, Igci YZ, Igci M,
Kırkbes S, Borazan E, Balik A, Yumrutaş Ö, Camci C, Cakmak EA, et
al: The association of the expression of miR-122-5p and its target
ADAM10 with human breast cancer. Mol Biol Rep. 42:497–505. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yan Y, Zhang F, Fan Q, Li X and Zhou K:
Breast cancer-specific TRAIL expression mediated by miRNA response
elements of let-7 and miR-122. Neoplasma. 61:672–679. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang B, Wang H and Yang Z: MiR-122
inhibits cell proliferation and tumorigenesis of breast cancer by
targeting IGF1R. PLoS One. 7:e470532012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Peng Y, Li C, Luo DC, Ding JW, Zhang W and
Pan G: Expression profile and clinical significance of microRNAs in
papillary thyroid carcinoma. Molecules. 19:11586–11599. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Stilling G, Sun Z, Zhang S, Jin L, Righi
A, Kovācs G, Korbonits M, Scheithauer BW, Kovacs K and Lloyd RV:
MicroRNA expression in ACTH-producing pituitary tumors:
up-regulation of microRNA-122 and −493 in pituitary carcinomas.
Endocrine. 38:67–75. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang Y, Xing QF, Liu XQ, Guo ZJ, Li CY and
Sun G: MiR-122 targets VEGFC in bladder cancer to inhibit tumor
growth and angiogenesis. Am J Transl Res. 8:3056–3066.
2016.PubMed/NCBI
|
